Cannabryl conducted India’s first clinical trial on medical cannabis and cancer in 2023. The trial titled ‘Phyto-history of Vijaya extracts for its potential Phytocomponents’ was published in the International Journal of Phytomedicine.
The CBD research study concludes that Cannabis sativa extracts have maximum solubility in organic solvents such as acetic acid, benzene, and dichloromethane.
The crude extracts obtained using a menthol: acetic acid-based extraction method contain various biological compounds, including terpenoids, glycosides, alkaloids, flavonoids, steroids, tannins, phenols, and saponins. These phytochemicals indicate the potential of Cannabis sativa as a source of therapeutic constituents for novel medicines.
The extraction method is efficient, biodegradable, and has acceptable toxicity, making it a safer and more sustainable alternative to common organic solvents for extracting phytocannabinoids.
TLC analysis and statistical calculations suggest the reliability of certain mobile phase systems for cannabinoid analysis. Further research is needed to assess the safety and utilization of Cannabis sativa leaf extracts, as proposed by previous studies on other plants. The findings highlight the potential of cannabis in the development of herbal medicinal products for specific medical conditions.
https://ijp.arjournals.org/index.php/ijp/issue/view/48
The company along with renowned oncologist surgeons like Dr Ganesh, Chief oncogenetic scientist of India, Dr Mahendra Pal & Dr Ankit Jain wrote another CBD research study titled’ Phyto-efficiency of Vijaya Extract for Normal Cell Protection and Its Anticancer Efficiency Against Breast Cancer Xenograft’ . It was recently accepted for publication in Research and Reviews: A Journal of Oncology and Hematology, Volume 11, Issue 3 (December 2022).